Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • 60 years of age or • a platelet count > 1,000 x 10 9 /l or • a history of thrombo-haemorrhagic events.
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • > 60 years of age or • A platelet count > 1000 x 10 9 /l or • A history of thrombo-haemorrhagic events.
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • >60 years of age or • a platelet count > 1000 x 10 9 /l or • a history of thrombo-haemorrhagic events.
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • > 60 years of age or • a platelet count > 1000 x 10 9 /l or • a history of thrombo-haemorrhagic events.
Anagrelide Glenmark 0.5 mg Capsule, hard is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: • >60 years of age or • a platelet count > 1000 x 10 9 /l or • a history of thrombo-haemorrhagic events.
Anagrelide AOP is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients. An at high risk essential thrombocythaemia patient is defined by one or more of the following features: - Age ≥ 60 years - Platelet count ≥ 1.000 x 10 9 /l - Increase of platelet count ≥ 300 x 10 9 /l within 3 months - Severe thrombohaemorrhagic or ischaemic symptoms in anamnesis - Vascular risk factors
Xagrid is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk essential thrombocythaemia patient is defined by one or more of the following features: • >60 years of age or • a platelet count >1000 x 10 9 /l or • a history of thrombo-haemorrhagic events.